netFormulary George Eliot Hospital NHS
NHS Trust  
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
Notes:

Chapter complete - updated July 18

 Details...
01.05.03  Expand sub section  Drugs affecting the immune response
Cytotoxic Drug Azathioprine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber SC
  • Available as 25mg & 50mg tablets £ (both strengths and all pack sizes)
 
Link  Azathioprine - Coventry and Warwickshire APC Shared Care Agreement
   
Ciclosporin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
  • Available as capsules £-££/30 capsules (depending on strength)
  • MHRA specify that ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands - NEORAL is the preferred brand at GEH
  • Specialist only for Ulcerative colitis (shared care for other indications)
 
   
Cytotoxic Drug Mercaptopurine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber SC
  • Available as tablets ££/25 tablets
 
Link  Mercaptopurine - Coventry and Warwickshire APC Shared Care Agreement
   
Cytotoxic Drug Methotrexate
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
  • Available as:
    • Tablets - 2.5mg tablets preferred as per NPSA alert ££/100 tablets
    • S/C injection £/pre-filled pen
  • Specialist only for Crohn's disease (shared care for other indications)
 
   
TofacitinibBlack Triangle (Xeljanz®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
BlueTeq

 

 

  • Manufacturer advises reduce dose to 5mg once daily with concurrent use of potent CYP3A4 inhibiitors or drugs which are both moderate CYP3A4 and potent CYP2C19 inhibitors.
  • Manufacturer advises patients should receive all recommended vaccinations before starting treatment; live vaccines should be given at least 2 weeks, but preferably 4 weeks before treatment initiation.
  • Manufacturer advises consideration of antituberculosis therapy prior to initiation of tofacitinib in patients with previously untreated latent TB.
 
   
01.05.03  Expand sub section  Cytokine inhibitors
Adalimumab (Hyrimoz® Humira®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
High Cost Medicine
Homecare
BlueTeq
  • Available as injection £££££
 
Link  NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Link  NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
   
Golimumab (Simponi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
High Cost Medicine
Homecare
BlueTeq
  • Available as injection £££££
 
Link  NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
   
Ustekinumab (Stelara®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
High Cost Medicine
Homecare
BlueTeq
  • Available as injection £££££
 
Link  NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
   
Infliximab (Remicade®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
High Cost Medicine
BlueTeq
  • Available as injection ££££
 
Link  NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
Link  NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Link  NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Link  NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
   
01.05.03  Expand sub section  Vedolizumab
Vedolizumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red SO
High Cost Medicine
BlueTeq
  • Available as injection £££££
 
Link  NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Link  NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red SO

SPECIALIST ONLY - These drugs are deemed to be not appropriate for prescribing by GPs. Specialists should not ask GPs to prescribe these drugs.   

Green SI

SPECIALIST INITIATED - These drugs must be initiated, i.e. the first dose prescribed, by the specialist and then may be continued when appropriate by the patients GP following communication from the specialist.   

Green SA

SPECIALIST ADVISED – Specialists may simply advise a patients GP to initiate these drugs themselves after they have made an initial assessment.   

Amber SC

SHARED CARE - Responsibility for prescribing may be transferred from secondary to primary care with the agreement of an individual GP and when agreed shared care arrangements have been established. The specialist MUST stabilize the patient before asking for care to be transferred. Only specialists should initiate these drugs. Prescribing should be transferred to GPs according to an Shared Care Agreement [SCA]   

netFormulary